^
Association details:
| Biomarker: | DKK1 overexpression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Tevimbra (tislelizumab) (PD1 inhibitor) + sirexatamab (DKN-01) (DKK1 protein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial
Published date:
11/08/2022
Excerpt:
The combination of D + TS represents a well-tolerated, active chemotherapy-free combination in previously treated DKK1-high IO naïve GEA pts. Encouraging durable activity was observed particularly in DKK1 high/vCPS≥10 cohort: ORR 45%, DCR 73%.
DOI:
10.1136/jitc-2022-SITC2022.0553
Source:
Title:
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
Published date:
01/18/2022
Excerpt:
The combination of D/TS + CAPOX represents a well-tolerated, active 1L combination, particularly for DKK1-high patients consistent with the proposed mechanism of action.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2022.40.4_suppl.292
Trial ID:
Source:
Title:
1384P - DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Published date:
09/13/2021
Excerpt:
...report response and survival outcomes in GEA patients (pts) treated with D + tislelizumab (T) + capecitabine/oxaliplatin (CAPOX) as a first line therapy....In RE DKK1 high pts (n=7) there was an ORR of 100% (6 PR, 1 NE) compared with DKK1 low pts (n=9) ORR of 56% (5 PR, 4 SD).
Secondary therapy:
CAPOX
Trial ID:
